2.39
price down icon0.42%   -0.010
after-market After Hours: 2.35 -0.04 -1.67%
loading
Cytomx Therapeutics Inc stock is traded at $2.39, with a volume of 1.33M. It is down -0.42% in the last 24 hours and up +6.22% over the past month. CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
See More
Previous Close:
$2.40
Open:
$2.4
24h Volume:
1.33M
Relative Volume:
0.28
Market Cap:
$192.68M
Revenue:
$101.21M
Net Income/Loss:
$-569.00K
P/E Ratio:
-119.50
EPS:
-0.02
Net Cash Flow:
$-56.88M
1W Performance:
+0.42%
1M Performance:
+6.22%
6M Performance:
+181.11%
1Y Performance:
+59.33%
1-Day Range:
Value
$2.35
$2.41
1-Week Range:
Value
$2.32
$2.47
52-Week Range:
Value
$0.40
$3.095

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Name
Name
Cytomx Therapeutics Inc
Name
Phone
650.515.3185
Name
Address
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Name
Employee
121
Name
Twitter
@cytomxinc
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
CTMX's Discussions on Twitter

Compare CTMX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CTMX
Cytomx Therapeutics Inc
2.39 378.11M 101.21M -569.00K -56.88M -0.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
460.83 120.60B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.63 60.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.79 42.87B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
595.19 36.23B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.51 31.54B 3.81B -644.79M -669.77M -6.24

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

Date Action Analyst Rating Change
May-15-25 Upgrade H.C. Wainwright Neutral → Buy
Apr-14-25 Resumed Piper Sandler Overweight
May-28-24 Upgrade Piper Sandler Neutral → Overweight
May-09-24 Upgrade Wedbush Neutral → Outperform
May-06-24 Upgrade Jefferies Hold → Buy
Apr-22-24 Upgrade JP Morgan Underweight → Neutral
Nov-14-22 Downgrade BMO Capital Markets Outperform → Market Perform
Jul-07-22 Downgrade Jefferies Buy → Hold
Jul-07-22 Downgrade Mizuho Buy → Neutral
Jul-07-22 Downgrade Piper Sandler Overweight → Neutral
Jul-07-22 Downgrade Wedbush Outperform → Neutral
Jun-24-22 Initiated BMO Capital Markets Outperform
Jan-18-22 Upgrade Barclays Underweight → Overweight
Nov-15-21 Initiated BTIG Research Buy
May-28-21 Downgrade Barclays Equal Weight → Underweight
Mar-29-21 Initiated JP Morgan Overweight
Mar-23-21 Upgrade Jefferies Hold → Buy
Sep-22-20 Downgrade Guggenheim Buy → Neutral
Jun-01-20 Downgrade Jefferies Buy → Hold
May-14-20 Reiterated H.C. Wainwright Buy
Mar-24-20 Upgrade Wedbush Neutral → Outperform
Mar-04-20 Initiated Barclays Equal Weight
Nov-20-19 Initiated Guggenheim Buy
Nov-11-19 Downgrade Wedbush Outperform → Neutral
Jun-13-19 Initiated Mizuho Buy
May-14-19 Initiated Cantor Fitzgerald Overweight
Mar-11-19 Initiated Barclays Overweight
Nov-26-18 Initiated Piper Jaffray Overweight
Oct-15-18 Initiated Goldman Neutral
Sep-13-18 Initiated H.C. Wainwright Buy
Jun-01-18 Initiated SunTrust Buy
Jan-05-18 Initiated Citigroup Buy
Sep-08-17 Initiated Wedbush Outperform
Mar-27-17 Initiated H.C. Wainwright Buy
Mar-02-17 Initiated Instinet Buy
Jan-03-17 Downgrade Oppenheimer Outperform → Perform
Nov-02-15 Initiated Oppenheimer Outperform
View All

Cytomx Therapeutics Inc Stock (CTMX) Latest News

pulisher
04:05 AM

What are analysts’ price targets for CytomX Therapeutics Inc. in the next 12 monthsFree Wealth Planning Blueprint - jammulinksnews.com

04:05 AM
pulisher
Jul 27, 2025

What institutional investors are buying CytomX Therapeutics Inc. stockGet expert analysis on top stock picks - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

How strong is CytomX Therapeutics Inc. company’s balance sheetNavigate market volatility with smart strategies - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 26, 2025

What makes CytomX Therapeutics Inc. stock price move sharplyFree Access to Community with 300% Return - metal.it

Jul 26, 2025
pulisher
Jul 25, 2025

What drives CytomX Therapeutics Inc. stock priceStrong return on assets - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

CytomX (CTMX) Shares Promising Early Results for CRC Drug Candidate - Yahoo Finance

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about CytomX Therapeutics Inc. stockSkyrocketing returns - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

CytomX Therapeutics Inc. Stock Analysis and ForecastExceptional return forecasts - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

10 Best Performing Penny Stocks So Far in 2025 - Insider Monkey

Jul 25, 2025
pulisher
Jul 20, 2025

Is CytomX Therapeutics Inc. a good long term investmentFree Stock Market Return Analysis - Autocar Professional

Jul 20, 2025
pulisher
Jul 16, 2025

Why CytomX Therapeutics Inc. stock attracts strong analyst attentionBalanced Risk Reward Portfolio - Newser

Jul 16, 2025
pulisher
Jul 15, 2025

How CytomX Therapeutics Inc. stock performs during market volatilityProtected Capital Trading Plan - Newser

Jul 15, 2025
pulisher
Jul 10, 2025

The Future of Allogene Therapeutics Inc: Analyzing ALLO - investchronicle.com

Jul 10, 2025
pulisher
Jul 10, 2025

Pliant Therapeutics Inc (PLRX) Stock: Navigating a Year of Volatility - investchronicle.com

Jul 10, 2025
pulisher
Jul 09, 2025

CTMX SEC FilingsCytomx Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Jul 09, 2025
pulisher
Jul 06, 2025

Do CytomX Therapeutics' (NASDAQ:CTMX) Earnings Warrant Your Attention? - Yahoo Finance

Jul 06, 2025
pulisher
Jul 03, 2025

CytomX Q2 2025 presentation slides: CX-2051 shows promising Phase 1 results in CRC By Investing.com - Investing.com South Africa

Jul 03, 2025
pulisher
Jul 03, 2025

CytomX Q2 2025 presentation slides: CX-2051 shows promising Phase 1 results in CRC - Investing.com

Jul 03, 2025
pulisher
Jun 25, 2025

Certain Pre-Funded warrants of CytomX Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 26-JUN-2025. - MarketScreener

Jun 25, 2025
pulisher
Jun 17, 2025

CytomX Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView

Jun 17, 2025
pulisher
Jun 17, 2025

CytomX Therapeutics CEO Sells Shares to Meet Tax Obligations - TradingView

Jun 17, 2025
pulisher
Jun 13, 2025

CytomX Therapeutics Approves Key Amendments at Annual Meeting - TipRanks

Jun 13, 2025

Cytomx Therapeutics Inc Stock (CTMX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.09
price down icon 1.32%
$37.06
price up icon 1.06%
$101.75
price down icon 2.12%
$27.45
price down icon 4.26%
$112.79
price down icon 2.19%
biotechnology ONC
$294.51
price up icon 1.04%
Cap:     |  Volume (24h):